Kura Oncology to Host Virtual Investor Event on December 9, 2024

KURA 12.02.2024

Full Press ReleaseSEC FilingsOur KURA Tweets

About Gravity Analytica

Recent News

  • 01.06.2025 - Kura Oncology Announces Senior Executive Promotions
  • 12.09.2024 - Kura Oncology ASH Virtual Investor Event
  • 12.09.2024 - Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH

SAN DIEGO,Dec. 02, 2024(GLOBE NEWSWIRE) --Kura Oncology, Inc.(NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at8:00 a.m. ET/5:00 a.m. PTonMonday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66thAmerican Society of Hematology(ASH) Annual Meeting inSan Diego.

The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be availablehereand in the Investors section of Kura’s website, with an archived replay available shortly after the event.

AboutKura Oncology

Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from theU.S. Food and Drug Administrationfor the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). InNovember 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website athttps://kuraoncology.com/and follow us onXandLinkedIn.

Kura Contacts

Investors:Pete De SpainExecutive Vice President, Investor Relations &Corporate Communications(858) 500-8833pete@kuraoncology.com

Media:Cassidy McClainVice PresidentInizio Evoke Comms(619) 849-6009cassidy.mcclain@inizioevoke.com

Primary Logo

Source: Kura Oncology, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com